Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Korosho Announces Revision of Precautions in Prazaxa Package Insert
October 10, 2011
- Decline in Research by Univ. Hospital Doctors Presents “Alarming Situation”: MEXT Official
October 10, 2011
- HPV Vaccines Competing for Public Subsidies; Are Parents Avoiding Vaccination by OB/GYN Doctors?
October 10, 2011
- MHLW to Set Up New System to Support Ultra-Orphan Drug Development
October 7, 2011
- Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010
October 6, 2011
- MHLW Issues GL for Clinical Evaluation for Renal Anemia Drugs
October 5, 2011
- PMDA Invites Opinions on Candidate Drugs for JP Listing
October 5, 2011
- MHLW to Adopt Self-Evaluation by Generic Drug Makers for Stable Supply
October 5, 2011
- Korosho to Support Pharmacies’ Participation in Home Healthcare
October 5, 2011
- FPMAJ States Difficulty in Identifying Anticancer Drugs in Terms of Adverse Reactions
October 4, 2011
- MHLW Intends to Improve Self-sufficiency Ratio in HBIG Preparation
October 4, 2011
- Partial Change in Approval Is Not Necessary for 14 Products Including Allegra: PFSB
October 4, 2011
- Bill for Healthcare Reform for Elderly to Be Submitted to 2012 Diet: Health Minister
October 4, 2011
- METI Budget Request Includes ¥3.3 Bil. to Promote “Healthcare Industry Creation”
October 3, 2011
- Mr Akagawa of ELD Stresses Need for Closer East Asian Cooperation to Promote Multinational Trials
October 3, 2011
- Health Insurance Committee Unable to Agree on Proposed Fixed-sum Examination Fee
October 3, 2011
- Obama Administration’s Deficit-reduction Plan Calls For Shorter Exclusivity Period for Biologics
October 3, 2011
- Nat’l Medical Expenditure Rose 3.4% to Record ¥36,006.7 Billion in FY2009: MHLW
September 30, 2011
- MHLW Drug Subcommittee Withholds Approval of Additional Indication for Epogin
September 30, 2011
- MHLW to Request Perpetuation of “Add-on Credits,” “Credits for High-level R&D Investment”
September 29, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…